Cost effectiveness of omalizumab for severe asthma in Colombia

References

• To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet L-P. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12(1):204. doi:10.1186/1471-2458-12-204.
   PubMed Web of Science ®Google Scholar
• McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs. 2013;73(11):1197–1212. doi:10.1007/s40265-013-0085-4.
   PubMed Web of Science ®Google Scholar
• Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593–610. doi:10.1111/all.12815.
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi:10.1111/all.14221.
   PubMed Web of Science ®Google Scholar
• Global Iniciative for Asthma Management and Prevention 2020. Available from: www.ginaasthma.org.
   Google Scholar
• Veettil SK, Vincent V, Shufelt T, Behan E, Syeed MS, Thakkinstian A, Young DC, Chaiyakunapruk N. Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies. J Asthma. 2023;60(9):1702–1714.
   PubMed Web of Science ®Google Scholar
• Tugay D, Top M, Aydin Ö, Bavbek S, Damadoğlu E, Öner Erkekol F, Koca Kalkan I, Kalyoncu AF, Karakaya G, Oğuzülgen IK, et al. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey. J Med Econ. 2023;26(1):720–730. doi:10.1080/13696998.2023.2209417.
   PubMed Web of Science ®Google Scholar
• Espinosa O, Rodríguez-Lesmes P, Orozco L, Ávila D, Enríquez H, Romano G, Ceballos M. Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia. Health Policy Plan. 2022;37(3):359–368. doi:10.1093/heapol/czab146.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559. doi:10.1002/14651858.CD003559.pub4.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh K-M, Ramos S, Canonica GW, Hedgecock S, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi:10.1111/j.1398-9995.2004.00772.x.
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, Griffin NM, Chipps BE. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: evidence From PROSPERO, A Prospective Real-World Study. J Allergy Clin Immunol Pract. 2019;7(1):156–164 e1. doi:10.1016/j.jaip.2018.04.043.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483–1492. doi:10.1016/j.rmed.2007.01.011.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Bereza BG, Nielsen TA, Hemels ME. Utilities for asthma and COPD according to category of severity: a comprehensive literature review. J Med Econ. 2015;18(7):550–563. doi:10.3111/13696998.2015.1025793.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22–27. doi:10.3132/pcrj.2007.00002.
   PubMedGoogle Scholar
• Departamento, Nacional, (DANE). DE. Archivo Nacional de Datos 2019. Available from https://sitios.dane.gov.co/anda-index/.
   Google Scholar
• Florez-Tanus A, Parra D, Zakzuk J, Caraballo L, Alvis-Guzman N. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J. 2018;11(1):26. doi:10.1186/s40413-018-0205-4.
   PubMed Web of Science ®Google Scholar
• Estadisticas DAN. Índice de Precios al Consumidor – IPC. 2020. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/precios-y-costos/indice-de-precios-al-consumidor-ipc.
   Google Scholar
• Consortium YHE. Net Monetary Benefit. 2016. Available from: https://yhec.co.uk/glossary/net-monetary-benefit/.
   Google Scholar
• Gaviria A, Gonzalez CP, Munoz CG, Morales AA. The debate on regulating biotechnology drugs: Colombia in the international context. Rev Panam Salud Publica. 2016;40(1):40–47.
   PubMed Web of Science ®Google Scholar
• Ramires MA, Guzman G, Delgado CA. Revision del uso de los medicamentos biosimilares vs biologicos implicaciones para la salud en Colombia. 2015. Available from: https://repository.urosario.edu.co/bitstream/handle/10336/12196/REVISI%C3%93N%20DEL%20USO%20DE%20LOS%20MEDICAMENTOS%20BIOSIMILARES%20VS.%20BIOL%C3%93GICOS%20%20IMPLICACIONES%20PARA%20LA%20SALUD%20EN%20COLOMBIA.pdf?sequence=1&isAllowed=y.
   Google Scholar
• Sullivan PW, Li Q, Bilir SP, Dang J, Kavati A, Yang M, Rajput Y. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2020;36(1):23–32. doi:10.1080/03007995.2019.1660539.
   PubMed Web of Science ®Google Scholar
• Jefferson Antonio B, Patino DG, Cossio-Giraldo YE. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma. J Asthma. 2022;59(10):2016–2023.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Cost-utility of omalizumab for the treatment of uncontrolled moderate-to-severe persistent pediatric allergic asthma in a middle-income country. Pediatr Pulmonol. 2021;56(9):2987–2996. doi:10.1002/ppul.25541.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231–250. doi:10.1016/j.jval.2013.02.002.
   PubMed Web of Science ®Google Scholar
• Sánchez J, Morales E, Santamaria L-C, Acevedo A-M, Calle A, Olivares M, Gomez C, Amaya D, Cardona R. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021;14(3):100520. doi:10.1016/j.waojou.2021.100520.
   PubMed Web of Science ®Google Scholar